Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To evaluate the 2-year safety of ranibizumab as assessed by type, rate and severity of serious and non-serious, ocular and non-ocular adverse events.
Inclusion criteria
- Choroidal neovascularization not related to wet Age-related macular degeneration (wAMD), pathologic myopia (PM)or Pseudoxanthoma elasticum (PXE), as well as in Macular Edema (ME) not related to Retinal Vein Occlusion (RVO) or Diabetic macular edema (DME) and other ocular neovascularization and/or complication such as Rubeosis Iridis and Neovacular Glaucoma and Proliferative Diabetic Retinopathy requiring Vitrectomy